The Latest Headlines at American Banking and Market News
Cidara Therapeutics (NASDAQ:CDTX) Given Buy Rating at Needham & Company LLC
Needham & Company LLC restated their buy rating on shares of Cidara Therapeutics (NASDAQ:CDTX – Free Report) in a research report sent to investors on Thursday, Benzinga reports. They currently have a $25.00 price target... More of this article »
Ovid Therapeutics (NASDAQ:OVID) Earns “Buy” Rating from HC Wainwright
HC Wainwright reissued their buy rating on shares of Ovid Therapeutics (NASDAQ:OVID – Free Report) in a report released on Thursday, Benzinga reports. They currently have a $9.00 price target on the stock. Other research analysts... More of this article »
Immatics (NASDAQ:IMTX) Price Target Raised to $16.00
Immatics (NASDAQ:IMTX – Free Report) had its target price hoisted by Mizuho from $14.00 to $16.00 in a research report report published on Thursday morning, Benzinga reports. They currently have a buy rating on the stock. Immatics... More of this article »
Barinthus Biotherapeutics’ (BRNS) Buy Rating Reiterated at HC Wainwright
HC Wainwright restated their buy rating on shares of Barinthus Biotherapeutics (NASDAQ:BRNS – Free Report) in a research report released on Thursday, Benzinga reports. The brokerage currently has a $8.00 target price on the... More of this article »
Needham & Company LLC Reiterates “Hold” Rating for Cisco Systems (NASDAQ:CSCO)
Needham & Company LLC reissued their hold rating on shares of Cisco Systems (NASDAQ:CSCO – Free Report) in a research report released on Thursday, Benzinga reports. Several other brokerages have also recently commented... More of this article »
Needham & Company LLC Reiterates “Buy” Rating for Infinera (NASDAQ:INFN)
Needham & Company LLC reissued their buy rating on shares of Infinera (NASDAQ:INFN – Free Report) in a research note published on Thursday, Benzinga reports. The brokerage currently has a $10.00 price objective on the communications... More of this article »
NorthWestern Energy Group (NYSE:NWE) PT Raised to $52.00
NorthWestern Energy Group (NYSE:NWE – Free Report) had its price target raised by Mizuho from $51.00 to $52.00 in a report published on Thursday morning, Benzinga reports. Mizuho currently has a neutral rating on the stock. Other... More of this article »
Magnite (NASDAQ:MGNI) Given “Buy” Rating at Needham & Company LLC
Needham & Company LLC reaffirmed their buy rating on shares of Magnite (NASDAQ:MGNI – Free Report) in a research note issued to investors on Thursday morning, Benzinga reports. The brokerage currently has a $15.00 target... More of this article »
Quaker Chemical (NYSE:KWR) Now Covered by Analysts at Piper Sandler
Piper Sandler started coverage on shares of Quaker Chemical (NYSE:KWR – Free Report) in a report issued on Thursday, MarketBeat Ratings reports. The brokerage issued an overweight rating and a $220.00 target price on the specialty... More of this article »
Needham & Company LLC Raises Impinj (NASDAQ:PI) Price Target to $195.00
Impinj (NASDAQ:PI – Free Report) had its target price hoisted by Needham & Company LLC from $160.00 to $195.00 in a research report sent to investors on Thursday morning, Benzinga reports. The brokerage currently has a buy... More of this article »
Mereo BioPharma Group (NASDAQ:MREO) Stock Rating Reaffirmed by Needham & Company LLC
Needham & Company LLC reissued their buy rating on shares of Mereo BioPharma Group (NASDAQ:MREO – Free Report) in a research report sent to investors on Thursday, Benzinga reports. Needham & Company LLC currently has... More of this article »
OncoCyte (NASDAQ:OCX) Receives “Buy” Rating from Needham & Company LLC
Needham & Company LLC reiterated their buy rating on shares of OncoCyte (NASDAQ:OCX – Free Report) in a report published on Thursday morning, Benzinga reports. Needham & Company LLC currently has a $4.25 price target... More of this article »
Eyenovia’s (EYEN) “Buy” Rating Reaffirmed at HC Wainwright
HC Wainwright reissued their buy rating on shares of Eyenovia (NASDAQ:EYEN – Free Report) in a research note published on Thursday, Benzinga reports. The brokerage currently has a $12.00 price target on the stock. Eyenovia Price... More of this article »